Visterra Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 122


  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $430M

Visterra General Information


Operator of a clinical-stage biopharmaceutical company designed to treat infectious diseases caused by organisms. The company's novel platform designs and engineers antibody-based biological products for the treatment of non-infectious diseases that are not being adequately addressed, thereby enabling the patients to seek the significant unmet need for effective therapies.

Contact Information

Formerly Known As
Parasol Therapeutics, Parasol Therapeutics Inc
Ownership Status
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Parent Company
Corporate Office
  • 275 Second Avenue
  • 4th Floor
  • Waltham, MA 02451
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Visterra Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 31-Aug-2018 $430M 00000 00000 Completed Generating Revenue
8. Later Stage VC (Series C) 05-Oct-2017 000.00 00000 00000 Completed Generating Revenue
7. IPO 10-Feb-2017 0000 00000 Cancelled Generating Revenue
6. Grant 29-Sep-2015 000.00 000.00 Completed Pre-Clinical Trials
5. Later Stage VC (Series B) 15-May-2014 0000 000.00 00000 Completed Pre-Clinical Trials
4. Later Stage VC (Series A) 02-Dec-2013 000.00 000.00 0000 Completed Startup
3. Debt - General 17-Sep-2010 000 000.00 Completed Startup
2. Seed Round 07-Dec-2009 $3.6M $5.64M 00.00 Completed Startup
1. Seed Round 28-Jan-2008 $2.04M $2.04M 00.000 Completed Startup
To view Visterra’s complete valuation and funding history, request access »

Visterra Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00.00 00.00 00 00.00 000
Series B 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 32,447,072 $0.000100 $1 $1 1x $1 28.51%
Seed 6,178,926 $0.000100 $1 $1 1x $1 5.43%
To view Visterra’s complete cap table history, request access »

Visterra Comparisons

HQ Location
Total Raised
Post Valuation
Operator of a clinical-stage biopharmaceutical company designed to treat infectious diseases caused by organisms. The co
Waltham, MA
122 As of 2023
00000 0000-00-00
000000&0 00000


didunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud e
0000 000000000
Pittsburgh, PA
00 As of 0000
000000000 000.00

000 00

laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repre
0000 000000000
Belfast, United Kingdom
00 As of 0000
0000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Visterra Competitors (104)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytoAgents Venture Capital-Backed Pittsburgh, PA 00 000.00 000000000 000.00
CV6 Therapeutics Venture Capital-Backed Belfast, United Kingdom 00 00.000 0000000000 00.000
Cellestia Venture Capital-Backed Basel, Switzerland 00 000.00 00000000000 000.00
Kbp Biosciences Venture Capital-Backed Princeton, NJ 00 0000 0000000000 0 0000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 104 competitors. Get the full list »

Visterra Patents

Visterra Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240132617-A1 Treatment of complement mediated diseases and disorders with c3b antibodies Pending 20-Sep-2022 00000000000
US-20240092921-A1 Antibody molecules to april and uses thereof Pending 25-Apr-2022 00000000000
US-20230390360-A1 Methods of using interleukin-2 agents Pending 11-Feb-2022 00000000000
US-20230383010-A1 Anti-idiotype antibody molecules and uses thereof Pending 07-Feb-2022 00000000000
US-20240041981-A1 Methods of using interleukin-2 agents Pending 01-Dec-2021 A61K38/2013
To view Visterra’s complete patent history, request access »

Visterra Executive Team (15)

Name Title Board Seat Contact Info
Brian Pereira MD President, Chief Executive Officer and Board Member
Todd Curtis Chief Financial Officer
Chris Kiefer JD Chief Administrative Officer, General Counsel and Corporate Secretary
Zachary Shriver Ph.D Chief Scientific Officer
Jean Bender Vice President of Pharmaceutical Sciences and Technology
You’re viewing 5 of 15 executive team members. Get the full list »

Visterra Board Members (16)

Name Representing Role Since
Brian Pereira MD Visterra President, Chief Executive Officer and Board Member 000 0000
You’re viewing 1 of 16 board members. Get the full list »

Visterra Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Visterra Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alexandria Venture Investments Venture Capital Minority 000 0000 000000 0
Allegheny Financial Group Asset Manager Minority 000 0000 000000 0
Bill & Melinda Gates Foundation Not-For-Profit Venture Capital Minority 000 0000 000000 0
CTI Life Sciences Fund Venture Capital Minority 000 0000 000000 0
Cycad Group Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

Visterra FAQs

  • When was Visterra founded?

    Visterra was founded in 2007.

  • Who is the CEO of Visterra?

    Brian Pereira MD is the CEO of Visterra.

  • Where is Visterra headquartered?

    Visterra is headquartered in Waltham, MA.

  • What is the size of Visterra?

    Visterra has 122 total employees.

  • What industry is Visterra in?

    Visterra’s primary industry is Biotechnology.

  • Is Visterra a private or public company?

    Visterra is a Private company.

  • What is the current valuation of Visterra?

    The current valuation of Visterra is 00000.

  • What is Visterra’s current revenue?

    The current revenue for Visterra is 00000.

  • How much funding has Visterra raised over time?

    Visterra has raised $123M.

  • Who are Visterra’s investors?

    Alexandria Venture Investments, Allegheny Financial Group, Bill & Melinda Gates Foundation, CTI Life Sciences Fund, and Cycad Group are 5 of 16 investors who have invested in Visterra.

  • Who are Visterra’s competitors?

    CytoAgents, CV6 Therapeutics, Cellestia, Kbp Biosciences, and NexImmune are some of the 104 competitors of Visterra.

  • When was Visterra acquired?

    Visterra was acquired on 31-Aug-2018.

  • Who acquired Visterra?

    Visterra was acquired by Otsuka Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »